A study to evaluate the effect of cilostazol after endovascular therapy for SFA lesions
- Conditions
- Peripheral arterial disease
- Registration Number
- JPRN-UMIN000011131
- Lead Sponsor
- Saiseikai yokohama city eastern hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Not provided
Patient criteria Patients who meet any of the following criteria should be excluded from the study: 1.Patients with or at risk of hemorrhagic complications or patients with bleeding* tendency *Bleeding such as hemophilia, capillary fragility, intracranial hemorrhage, gastrointestinal hemorrhage, urinary tract hemorrhage, hemoptysis, or vitreous hemorrhage may be aggravated. 2.Pregnant or potentially pregnant women 3.Patients with acute lower limb ischemia 4. Patients who are not eligible for the study in the opinion of the attending physician. Lesion criteria Lesions that meet any of the following criteria should be excluded from the study: 1.Remnant inflow (aorta-iliac artery lesion) 2.Severe calcification (lesions not expected to be appropriately expanded) 3.No arterial runoff below the knee
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Angiographic restenosis rate (12 months)(-1month+1month)
- Secondary Outcome Measures
Name Time Method Patency rate, ABPI, Cardiovascular events (death, MI, stroke), Lower limb vascular events, all cause mortality